ClinicalTrials.gg
RecruitingNCT07614425FINCATSUpdated Oct 2, 2026

Finnish Carpal Tunnel Surgery Study

An interventional study of Carpal tunnel release and Placebo surgery in Carpal Tunnel Syndrome, sponsored by Helsinki University Central Hospital. Recruiting at 2 sites in Finland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 2, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Carpal tunnel syndrome (CTS) is a common condition caused by pressure from a ligament on a nerve in the wrist, leading to pain, numbness, and weakness in the hand. Surgery to cut the ligament is often recommended when non-surgical treatments do not provide sufficient symptom relief, but it is unclear how much of the improvement is due to the surgery itself versus natural recovery or placebo effects.

The FINCATS study will compare standard carpal tunnel surgery with a placebo procedure in which the ligament is not cut. Participants and the healthcare staff caring for them after the procedure will not know which procedure was performed. The study's main question is whether cutting the ligament provides greater symptom relief than a placebo procedure. In addition, eligible patients who are not willing to participate in randomized setting are invited to join a parallel observational group. Participants in this observational group are treated within usual care pathway.

Participants in both the randomized and observational group will be followed for five years to assess symptom improvement, hand function, pain, quality of life, and any side effects. The goal is to provide reliable evidence to help patients and doctors make informed decisions about treatment.

02

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Randomised controlled trial
  • Placebo-controlled trial
  • Surgery
  • Carpal tunnel syndrome
  • Carpal tunnel release
03

In context

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

This study's planned enrollment of 180 is above the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years
  • Clinical manifestations of carpal tunnel syndrome: paresthesia and /or hypoesthesia in the distribution of the median nerve, possibly pain
  • Electrodiagnostically (ENMG or ENEG) verified compression of the median nerve at the carpal tunnel in the wrist, performed no more than a year before recruitment.
  • Duration of symptoms 3 months or longer
  • Patient living independently
  • Patient has not responded to the use of a resting splint supporting the wrist, nor to other possible conservative forms of treatment
  • Patient able and willing to give consent
  • The patient is willing to undergo surgical treatment for carpal tunnel syndrome.
  • The patient has access to a device that can be used to complete electronic symptom questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Work disability
  • Clinical findings of Abductor Pollicis Brevis atrophy
  • Symptoms and Electrodiagnostic findings of some other peripheral neural entrapment than carpal tunnel syndrome
  • Rheumatoid arthritis or other forms of systemic inflammatory disease
  • Diagnosed dementia
  • Neurologic disorders affecting the function of the hand
  • Other untreated systemic disorders or diseases with poor therapeutic balance: hypertension, epilepsy, pulmonary or cardiac disease, liver or renal insufficiency, diabetes mellitus, hypothyroidism, psychiatric disease
  • Other causes of pain and paresthesia in the hand
  • Previous trauma of the hand or wrist (e.g. distal radius fracture), which has resulted in compromised hand function
  • Previous carpal tunnel release in either hand
  • Previous nerve injury to the upper limb or cervical spine
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Carpal tunnel release

    Open carpal tunnel release: skin incision, division of the palmar aponeurosis, and transverse carpal ligament.

    Procedure: Carpal tunnel release

  • Placebo comparator
    Placebo surgery

    Placebo surgery: Skin incision and division of palmar aponeurosis

    Procedure: Placebo surgery

  • Other
    Observational arm

    Open carpal tunnel release: skin incision, division of the palmar aponeurosis, and division of the transverse carpal ligament. Observational group: eligible participants included to assess potential selection bias.

    Procedure: Carpal tunnel release

Interventions

  • ProcedureCarpal tunnel release

    Open carpal tunnel release: skin incision, division of the palmar aponeurosis, and transverse carpal ligament.

  • ProcedurePlacebo surgery

    Skin incision and division of the palmar aponeurosis

06

What researchers measure

Primary outcomes

  1. Patient acceptable symptom state (PASS)

    PASS is used as a binary global outcome using the following question: "Regarding your recovery from the carpal tunnel release, specifically pertaining to paresthesia, pain and overall function of the hand, would you be content if the clinical state of your hand would remain the same as it has been the past week?" Response options are: Yes, I would be content or No, I would not be content.

    Time frame: 4 months

Secondary outcomes

  1. Patient acceptable symptom state (PASS)

    PASS is used as a binary global outcome measure and will be assessed using the following question: "Regarding your recovery from the carpal tunnel release, specifically pertaining to paresthesia, pain and overall function of the hand, would you be content if the clinical state of your hand would remain the same as it has been the past week?" Response options are: Yes, I would be content or No, I would not be content.

    Time frame: 6 and 9 months and 1,2,3,4 and 5 years

  2. Global Impression of Improvement (PGI-I)

    A single-item patient-reported measure indicating overall perceived improvement since the start of treatment, rated on a 7-point scale from 1 (very much improved) to 7 (very much worse).

    Time frame: 4, 6 and 9 months and 1,2,3,4 and 5 years

  3. 6-Item carpal tunnel syndrome (CTS) symptoms scale

    The CTS-6 is a validated six-item patient-reported questionnaire used to assess the severity of carpal tunnel syndrome symptoms, including pain, numbness or tingling, and functional impairment, with scores ranging from 0 (least severe) and 26 (most severe). A score \>12 correlates with an 80% probability of CTS.

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  4. Patient-Specific Functional Scale (PSFS)

    The Patient-Specific Functional Scale (PSFS) is a patient-reported measure that assesses level of functional limitations in 3-5 activities identified as important by the patient and deemed difficult to perform by the patient, due to the hand condition. The PSFS is rated on an ordinal scale from 0 (unable to perform the activity) to 10 (able to perform the activity at the same level as before the disease.)

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  5. Numeric Pain Rating Scale (NRS)

    A patient-reported measure for pain intensity on an 11-point scale from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  6. Health-related quality of life (EuroQol 5-Dimension 5-Level (EQ-5D-5L) index value)

    EQ-5D-5L questionnaire, Finnish language version, using the Danish value set. Score ranges from values below 0 (health states considered worse than death) to 1.00 (full health), where higher scores indicate better health-related quality of life.

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  7. Health-related quality of life: EuroQol 5-Dimensions (EQ-5D) Visual Analogue Scale (VAS) (EQ VAS) )

    EQ-5D is a generic patient rated outcome measure (PROM) comprising five health dimensions (mobility, self-care, daily activities, pain/discomfort, anxiety/depression) and a VAS. EQVAS is a vertical visual analogue scale, on which patients rate their general health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  8. Harms

    Harms and healthcare contacts related to the operated hand will be collected systematically and unprompted using a standardized electronic case report files (eCRF). Events will be classified by type (Adverse event, Serious Adverse Event, Suspected Unexpected Serious Adverse Reaction), attribution, timing, and nature.

    Time frame: Intervention (intra-operative), at 4, 6 and 9 months and 1,2,3,4 and 5 years. In addition, unprompted contacts from participant

Other outcomes

  1. Pillar pain - interview

    Pillar pain will be assessed using two questions: 1. Do you have pain at rest in the palm of your hand? 2. Are you able to bear weight on your extended wrist and hand? Response options: Yes or No.

    Time frame: At recruitment and 1 and 4 months after intervention.

  2. Pillar pain - pressure pain thresholds

    Pillar pain will be assessed through pressure pain thresholds on thenar and hypothenar eminences with a digital algometer

    Time frame: At recruitment and 1 and 4 months after intervention.

  3. Pillar pain - palmar skin sensation

    Palmar skin sensation will be assessed at thenar and hypothenar eminences with a standard evaluation tool neuropen.

    Time frame: At recruitment and 1 and 4 months after intervention.

  4. Blinding fidelity

    Blinding fidelity will be assessed by asking participants which treatment group they believe they were allocated to. Response options will include "Carpal tunnel release," "Placebo intervention," or "Unsure."

    Time frame: At 4 months after intervention.

  5. Conduction velocity

    Nerve conduction velocities will be assessed in randomized participants using standard electroneurography techniques. Measurements will quantify median nerve function across the carpal tunnel to evaluate changes after intervention.

    Time frame: At 4 months after intervention.

  6. Medication

    Need for medication due to pain. Response options: Every day, On most days of the week, 1-2 times a week, Rarely 5. Never

    Time frame: At recruitment, 4, 6 and 9 months and 1,2,3,4 and 5 years

  7. Clinical examination

    Standard hand surgical clinical examination and provocation tests: Tinell, Tethro, Phalen and atrophy evaluation

    Time frame: At recruitment; at 4, and 12 months; and at 5 years after primary surgery.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD provided that current legislation permits it.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: After publication of main results, to be specified later

Access criteria: To be determined

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 35 months is above that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartActual
Jun 11, 2026
Primary completionEst.
May 30, 2029
CompletionEst.
Dec 31, 2035
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Wellbeing Services County of Pirkamaa, Tampere Central University Hospital is now Recruiting
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Wellbeing Services County of Pirkamaa, Tampere Central University Hospital is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07614425
Responsible party
Susanna Stjernberg-Salmela (Consultant in hand surgery, MD, PhD, Helsinki University Central Hospital) — Principal investigator
First posted
May 29, 2026
Start date
Jun 11, 2026
Primary completion
May 30, 2029 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Oct 2, 2026

Study contacts

Susanna Stjernberg-Salmela, MD, PhD
Contact
Susanna.Stjernberg-Salmela@hus.fi
0504274955 ext. +358
Kati MJ Jaatinen
Contact
kati.jaatinen@hus.fi
Teppo LN Järvinen, Professor
study director · Helsinki University Central Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion